Sinus Node Dysfunction Clinical Trial
— IMPROVE BradyOfficial title:
Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)
NCT number | NCT01643707 |
Other study ID # | IMPROVE Brady |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 2012 |
Est. completion date | January 31, 2019 |
Verified date | September 2021 |
Source | Medtronic Cardiac Rhythm and Heart Failure |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)
Status | Completed |
Enrollment | 1342 |
Est. completion date | January 31, 2019 |
Est. primary completion date | January 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient is at least 18 years of age - Patient's heart rate meets at least one of the following: - Patient has a sinus rate = 50 OR a junctional escape rhythm no faster than 50 - Patient has a history of exercise intolerance - Patient complains of general fatigue, shortness of breath, shortness of breath with exertion, syncope, light headed dizziness, palpitations, lethargy, dyspnea OR malaise within the last 30 days that are not related to other discovered causes (such as untreated hypothyroidism or anemia). - Patient (or patient's legally authorized representative) is willing and able to sign and date written Patient Consent Form/Patient Data Release Consent Exclusion Criteria: - Patient has type II 2nd degree AV block, High degree AV block (2:1, 3:1, 4:1 etc.) or 3rd degree AV block - Patient has recent history of blood loss - Patient has a medical history leading to suspicion of neurological disorder - Patient has a history of Chronic Atrial Fibrillation - Patient is enrolled or planning to participate in a concurrent drug and/or device study at any time during the course of this clinical study without documented pre-approval from the Medtronic study manager - Patient is not expected to survive for 12 months - Patient is anticipated to be unwilling or unable to comply with the clinical investigation plan |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital General de Agudos | Buenos Aires | |
Bangladesh | National Heart Foundation Hospital and Research Institute | Dhaka | |
Bangladesh | United Hospital Limited | Dhaka | |
India | Care Insitute of Medical Sciences | Ahmedabad | Gujarat |
India | RajaRajeswari Medical College & Hospital | Bangalore | Karnataka |
India | Madras Medical Mission Institute of Cardiovascular Diseases | Chennai | Tamil Nadu |
India | Max Devki Devi Heart and Vascular Institute | Delhi | |
India | The Mission Hospital | Durgapur | West Bengal |
India | CARE Hospitals | Hyderabad | Andhra Pradesh |
India | King George's Medical University | Lucknow | Uttar Pradesh |
India | Max Balaji Hospital | New Delhi | DL |
Mexico | Centro Medico Nacional de Occidente IMSS | Mexico City | |
Mexico | Hospital Central Militar | Mexico City | |
Mexico | UMAE Hospital de Cardiologia Centro Medico nacional Siglo XXI IMSS | Mexico City | |
Peru | Hospital Nacional Carlos Alberto Seguín Escobedo | Arequipa | |
Peru | Instituto Nacional Cardiovascular | Lima | |
Russian Federation | Amur State Medical Academy | Amur | Amur Oblast |
Russian Federation | Chelyabinsk Federal Center of Cardiovascular Surgery | Chelyabinsk | |
Russian Federation | Center of Modern Cardiology | Krasnoyarsk | |
Russian Federation | Federal Center of Cardio-Vascular Surgery | Krasnoyarsk | |
Uruguay | Casa de Galicia | Montevideo |
Lead Sponsor | Collaborator |
---|---|
Medtronic Cardiac Rhythm and Heart Failure |
Argentina, Bangladesh, India, Mexico, Peru, Russian Federation, Uruguay,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Absolute Change in the Proportion of Subjects Diagnosed With SND Before and After Intervention | The absolute change in the proportion of subjects diagnosed with SND before and after intervention | Up to 1 year post enrollment | |
Primary | The Absolute Change in the Proportion of Subjects Receiving Indicated Therapy Before and After Intervention | Outcome measure applies to subjects that receive a SND diagnosis | Up to 6 months post diagnosis | |
Secondary | The Proportion of Phase I Subjects Diagnosed With SND and the Number of Diagnoses That Result in Indicated Therapy | Enrolled subjects only with an SND diagnosis were reassessed at 6 and 12 months post enrollment were reassessed for IPG therapy. | SND diagnosis assessed at 6 and 12 months of follow-up from enrollment until resulting IPG therapy | |
Secondary | Change in Time to Diagnosis of SND Before and After Intervention | Time to diagnosis days (date of diagnosis - date of enrollment) | From date of enrollment until date of SND diagnosis, assessed up to 60 months | |
Secondary | Change in Time to Receiving an Indicated IPG Device for Subjects Diagnosed With SND Before and After Intervention | Time to implant in days (date of implant - date of diagnosis) | From date of SND diagnosis until date of therapy, assessed up to 6 months | |
Secondary | Difference in QoL Between Implant Visit and 6 Months Post-implant | The difference in quality of life was assessed using the SF-12 survey, with higher numbers indicating a better quality of life for the patient. The possible physical score ranges are between 24.0 and 56.6. The possible mental score ranges are between 19.1 and 60.8. Only the difference over time was reported. | between implant visit and 6 months post-implant | |
Secondary | Change in Zarit Quality of Life (QOL) Between Implant Visit and 6 Months Post-implant | The difference in caregiver burden was assessed using a Zarit survey, with lower numbers indicating a decreased burden or a better outcome for the caregiver. The possible range of scores was between 0 and 88. Only the difference in scores over time were reported. | between implant visit and 6 months post-implant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04093414 -
Left Bundle Area Versus Selective His Bundle Pacing
|
N/A | |
Enrolling by invitation |
NCT03903107 -
The Fluoroless-CSP Trial Using Electroanatomic Mapping
|
N/A | |
Completed |
NCT01688843 -
Safety and Performance Study of the INGEVITY Lead
|
N/A | |
Completed |
NCT03719040 -
Physiologic Pacing Registry
|
||
Completed |
NCT02027909 -
A Comparison of Rate Response Performance in Pacemaker Patients With an Indication of Sinus Node Dysfunction
|
||
Completed |
NCT00655213 -
Spontaneous Atrio Ventricular Conduction Preservation
|
Phase 4 | |
Recruiting |
NCT05186220 -
Cardioneuroablation Versus Pacemaker Implantation for the Treatment of Symptomatic Sinus Node Dysfunction
|
N/A | |
Recruiting |
NCT05766462 -
Allometric-Pace Study
|
||
Recruiting |
NCT05196126 -
Permanent Pacemaker Implantation or Cardioneuroablation in Sinus Node Dysfunction
|
N/A | |
Active, not recruiting |
NCT03607123 -
Atrial Fibrillation With Sinus Node Dysfunction: Intensive Device Follow-up
|
||
Completed |
NCT01170611 -
Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease
|
Phase 4 | |
Completed |
NCT03601754 -
Effectiveness of Closed Loop Stimulation (CLS) With His Bundle Lead Placement
|
N/A | |
Completed |
NCT01781078 -
ImageReady(TM) MR Conditional Pacing System Clinical Study
|
N/A | |
Active, not recruiting |
NCT05887323 -
LBBAP Data Collection Registry
|
||
Completed |
NCT04632641 -
Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
|
N/A | |
Completed |
NCT02586480 -
Evolution of the PR Interval in Patients Implanted With a Pacemaker Using the SafeR Mode
|
N/A |